Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

246
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
246
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

208
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
208
Nursing Clinical Information System01:27

Nursing Clinical Information System

1.2K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.2K
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H01:13

meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

6.6K
All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacist Interventions for Inhaled Medication Use in Chronic Obstructive Pulmonary Disease (COPD).

The Senior care pharmacist·2024
Same author

Patient Perspective: Vaccines for Older People.

The Senior care pharmacist·2023
Same author

The Patient Living With Diabetes.

The Senior care pharmacist·2022
Same author

Nitrofurantoin Use in Frail, Community-Dwelling, Older Adults with Renal Impairment.

The Senior care pharmacist·2019
Same author

Screening Tool of Older Person's Prescriptions/Screening Tools to Alert Doctors to Right Treatment Medication Criteria Modified for U.S. Nursing Home Setting.

Journal of the American Geriatrics Society·2016
Same author

Optimizing inhaler use by pharmacist-provided education to community-dwelling elderly.

Respiratory medicine·2015
Same journal

Can Technology Simplify Aging Care-or Just Shift the Complexity?

The Senior care pharmacist·2026
Same journal

Transitioning Medication-Related Home Visits to a Cognitively Accessible Digital Intervention in Home Care: A Practice Innovation Pilot.

The Senior care pharmacist·2026
Same journal

Perception of Technology to Support Medication Management Among Community-dwelling African American Older Adults.

The Senior care pharmacist·2026
Same journal

ASCP Policy Review Committee.

The Senior care pharmacist·2026
Same journal

Initial Evaluation of L-mMRC Severity Tool in Staging COPD in the Skilled Nursing Setting.

The Senior care pharmacist·2026
Same journal

Dispense This: How AI Is Reshaping Pharmacy's Clinical Services.

The Senior care pharmacist·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.9K

2025 New Drug Update (Part 2): Recent Approvals and Clinical Implications.

Sophie Friedman1, Kyle Akerman2, Carla Bouwmeester1

  • 11Northeastern University School of Pharmacy and Pharmaceutical Sciences, Boston, Massachusetts.

The Senior Care Pharmacist
|January 20, 2026
PubMed
Summary
This summary is machine-generated.

This review covers new drug approvals like dihydroergotamine mesylate, acoramidis, and gepotidacin. It offers insights for healthcare professionals on using these medications in older patients, focusing on safety and efficacy.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.6K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K

Related Experiment Videos

Last Updated: Jan 22, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.9K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.6K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K

Area of Science:

  • Geriatrics
  • Pharmacology
  • Internal Medicine

Background:

  • Polypharmacy and age-related physiological changes necessitate updated pharmacotherapy for older adults.
  • Optimizing medication management requires understanding new drug approvals.
  • Individualized pharmacotherapy is essential for geriatric patients.

Purpose of the Study:

  • To review recently approved medications relevant to older patient populations.
  • To provide insights into prescribing considerations, drug-drug interactions, and handling for new agents.
  • To support healthcare professionals in evaluating new therapeutic options for the elderly.

Main Methods:

  • Literature synthesis of the latest evidence on new drug approvals.
  • Focus on medications for migraine headaches, transthyretin amyloid cardiomyopathy, and urinary tract infections.
  • Analysis of prescribing considerations for older adults.

Main Results:

  • Review of Atzumi™ and Brekiya® (dihydroergotamine mesylate) for migraine headaches.
  • Discussion of Attruby™ (acoramidis) for transthyretin amyloid cardiomyopathy.
  • Examination of Blujepa® (gepotidacin) for uncomplicated urinary tract infections.

Conclusions:

  • New medications offer novel treatment options for specific conditions in older adults.
  • Careful consideration of prescribing factors, drug interactions, and administration is crucial.
  • This review aids clinicians in integrating new pharmacotherapies into geriatric care.